Sensei Biotherapeutics focuses on developing cancer therapies by targeting multiple nodes of biological pathways, particularly the PI3K/AKT/mTOR pathway. The company's lead program, PIKTOR, combines serabelisib and sapanisertib to enhance tumor suppression. Sensei Biotherapeutics operates in the clinical development of these therapies, with a pipeline that aims to expand into new indications and targets.
